Clinical Trial Update: An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating a Gallium-68 labeled FAPI tracer (Ga-FAPI-04) PET/CT for imaging patients with high-grade neuroendocrine tumors; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Ga-FAPI-04 PET/CT (Gallium-68 labeled fibroblast activation protein inhibitor PET/CT tracer)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Neuroendocrine Tumor | EARLY_Phase 1 | Status: RECRUITING